# Genmab A/S (GMAB.CO): MoatMap facts

As of 21 Nov 2026. Research data, not investment advice.

As of 21 Nov 2026, the MoatMap Score for Genmab A/S (GMAB.CO) is 68/100, ranked against 25,000+ stocks in 38 markets (Quality 60, Value 26, Momentum 79, each scored against its sector).

- MoatMap Score: 68/100, a percentile across 25,000+ stocks in 38 markets (100 is best).
- Quality 60, Value 26, Momentum 79: each a 0-100 percentile within Healthcare.
- Position: #8,383 overall, #853 in Healthcare.
- Listing: Denmark, CPH; Healthcare / Biotechnology.
- Last close: 3,469 DKK on 20 Nov 2026.
- Insider filings, last 180 days: directors sold USD 377K.

Source: https://moatmap.ai/stock/GMAB.CO
How the scores work: https://moatmap.ai/methodology
Does the score work? Each tenth of the ranking is tracked monthly: https://moatmap.ai/decile-tracker
